Velbastine Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Vinblastine sulfate

Indications/Uses

Hodgkin's disease (stage III & IV), lymphocytic lymphoma, histiocytic lymphoma; advanced stages of mycosis fungoides; advanced carcinoma of the testis; Kaposi's sarcoma & histiocytosis X. Choriocarcinoma resistant to other chemotherapeutic agents; breast carcinoma.

Click to view Velbastine detailed prescribing information

Dosage/Direction for Use

Adult 1st dose: 3.7 mg/m². 2nd dose: 5.5 mg/m², 3rd dose: 7.4 mg/m², 4th dose: 9.25 mg/m², 5th dose: 11.1 mg/m². Max: 18.5 mg/m². Childn 1st dose: 2.5 mg/m². 2nd dose: 3.75 mg/m², 3rd dose: 5 mg/m², 4th dose: 6.25 mg/m², 5th dose 7.5 mg/m². Max: 12.5 mg/m². Dose given once wkly.

Click to view Velbastine detailed prescribing information

Overdosage

View Velbastine overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity. Leukopenia, bacterial infection. Pregnancy & lactation.

Click to view Velbastine detailed prescribing information

Special Precautions

Patients w/ hepatic or renal disorder, bone marrow depression, infections, history of muscular or neural disease, chickenpox, presence of cachexia or ulcerated areas of the skin. Perform blood tests, liver & renal function tests frequently. Manifestation of bleeding tendency & infection. Leukopenia <2,000 WBC/mm³. Do not administer intrathecally. Avoid eye contamination. Women of childbearing potential. Childn. Elderly.

Click to view Velbastine detailed prescribing information

Use In Pregnancy & Lactation

Click to view Velbastine detailed prescribing information

Adverse Reactions

Leukopenia, thrombocytopenia, bleeding, anemia; nausea, vomiting, anorexia, dipsia, stomatitis, infection of the lip, abdominal pain, rectal bleeding, ileus, constipation, cacogeusia, indigestion; anaphylactoid syndrome (urticaria, dyspnea, angioedema); alopecia, blister, rash; paraesthesia, peripheral neuritis, loss of deep tendon reflexes, dysbasia, convulsion, arthralgia, myalgia, headache, dizziness, depression, hyposomnia, aspermia, gonad disorder; acute shortness of breath, severe bronchospasm; dysuria, flush, phlebitis, inj site pain, sphacelism, boil or wart, lymph node pain, tachycardia; cellulitis, phlebitis.

Click to view Velbastine detailed prescribing information

Drug Interactions

Concomitant use w/ other antineoplastic or radiotherapeutic agents. Enhanced drug action w/ erythromycin. May cause MI or cerebral infarction w/ vinca alkaloids.

Click to view Velbastine detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Velbastine detailed prescribing information

Storage

View Velbastine storage conditions for details to ensure optimal shelf-life.

Description

View Velbastine description for details of the chemical structure and excipients (inactive components).

Action

View Velbastine mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01CA01 - vinblastine ; Belongs to the class of plant alkaloids and other natural products, vinca alkaloids and analogues. Used in the treatment of cancer.

Regulatory Classification

Presentation/Packing

Form

Velbastine powd for inj 10 mg

Packing/Price

(vial) 1's

Velbastine

vinblastine

Manufacturer:

Korea United Pharma

Distributor:

Qualimed